Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Positive development in the USA continues SEK t Q4 24/25 Q4 23/24 May-April 24/25 May-April 23/24 Net sales 2,332 1,899 8,619 7,290 Operating profit (loss) -20,341 -41,490 -85,839 -126,845 Profit (loss) for the period -20,766 -39,532 -87,624 -124,823 Earnings per share after dilution -0.21 -0.47 -0.95 -2.14 Number of shares at the end of the period 97,786,384 84,055,560 92,569,248...
Read more
Lobe Sciences Ltd., (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) a leading biopharmaceutical company focused on breakthrough treatments for rare diseases, is advancing the development of its novel compound, Conjugated Psilocin™, following the April 14, 2025 spinout of the compound to the newly created Delaware corporation Cynaptec Pharmaceuticals, Inc. and signing of a key US$6 million investment non-brokered private placement agreement for preferred...
Read more
A highly anticipated and sought after AASCP meeting is back by popular demand slated for the fall of 2025. We are excited to invite you to one of the most dynamic events in the field of Regenrative Medicine! The Regenerative Medicine Fall Conference of 2025 will be taking place October 3-5 in Miami , Florida. Whether you are a season expert or just starting to explore the field, this conference offers all the knowledge, resources and networking...
Read more
NAYA Therapeutics, a clinical-stage biopharmaceutical company dedicated to pioneering the next generation of cancer immunotherapies, today announced that it is expanding its comprehensive hepatocellular carcinoma (HCC) pipeline with the addition of NY-700, a first-in-class GPC3-targeted Astatine-211 (211At) alpha radioimmunotherapy aiming to address residual disease, micro-metastasis, and post-immunotherapy failures. NAYA's HCC franchise also...
Read more
Next Gen Diagnostics (NGD) today announced that Dr. Lee Harrison, Professor of Epidemiology and Director of the Center for Genomic Epidemiology at the University of Pittsburgh (Pitt), has agreed to chair NGD's Infection Prevention Advisory Board, and that Dr. Alex Sundermann, Assistant Professor of Epidemiology at Pitt and a widely recognized expert in genomic outbreak detection, has accepted a role as NGD's Lead Consultant for Infection...
Read moreTharimmune, Inc. (NASDAQ:THAR), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology, today announced significant appointments to its executive leadership and board of directors, reinforcing its commitment to advancing its pipeline and strategic initiatives. The Company is advancing its lead candidate TH104 specifically designed through a buccal film formulation to deliver an...
Read more
Aspira Women's Health Inc. a bio-analytical-based women's health company focused on gynecologic disease diagnostics, and Dorsata, a leading clinical decision-support and provider workflow platform for women's health, announced today the official launch of a new adnexal mass clinical decision support module in partnership with Dorsata, a leading women's health electronic health record software solutions company. Dorsata's platform is currently...
Read more
Moolec Science SA (NASDAQ:MLEC) ("The Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, today announced the successful closing of its previously announced strategic business combination (the "Business Combination") with Bioceres Group Limited ("Bioceres Group"), Gentle Technologies Corp ("Gentle Tech"), and Nutrecon LLC ("Nutrecon"). With the closing, Moolec emerges...
Read more
Alligator Bioscience (STO:ATORX) - Lund, Sweden, 17 June 2025 - Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumor-directed immunotherapies, today announced that the European Medicines Agency (EMA) has provided positive scientific advice supporting the overall design of the planned Phase 3 study of mitazalimab in metastatic pancreatic cancer. The advice confirms that the proposed Phase 3 study...
Read more
uBriGene Biosciences, a leading cell and gene therapy CDMO, is proud to announce the launch of its fully characterized, ready-to-use induced pluripotent stem cell (iPSC) banks. Developed using uBriGene's proprietary RNA-LNP reprogramming technology, these iPSC banks are now available to support research, translational development, and clinical applications worldwide. uBriGene's iPSC seed banks and master cell banks (MCBs) are generated in...
Read more
AbTherx, a biotechnology company with innovative technologies that enable therapeutic antibody discovery against challenging targets, today announced a research collaboration with GPCR Therapeutics, a clinical-stage biopharmaceutical company, to discover and develop therapeutic antibodies targeting G protein-coupled receptors (GPCRs) for one target, with the potential to expand to additional targets. AbTherx's antibody discovery platform is...
Read more
Adolore BioTherapeutics ("Adolore" or the "Company"), a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain and neurological disorders, today announced the publication of its manuscript titled, "Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain Via the Intra-Articular Route in Mice1," in the peer-reviewed journal, Molecular Therapy. Roy Clifford...
Read more
NeuroEM Therapeutics®, an award-winning clinical-stage biotechnology research company pioneering the use of radio frequencies to reverse Alzheimer's disease, has closed initial rounds totaling $1.33 million of a $5 million equity raise with BlueLake.vc. The Series A round supports continued progress toward commercialization of NeuroEM's Transcranial Electromagnetic Treatment (TEMT-RF) to prevent and treat cognitive decline caused by aging or...
Read more
Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has provided feedback supporting the selection of the 900 µg/kg dose of its CD40 agonist mitazalimab for the planned Phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC). This positive regulatory feedback confirms Alligator's dose...
Read more
BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced updated positive data from the ongoing Phase 2a dose expansion study of BI-1808 monotherapy in cutaneous T-cell lymphoma (CTCL). The data will be presented in a poster at the European Hematology Association (EHA) 2025...
Read more
Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Strong efficacy and survival outcomes with bexmarilimab in high-risk MDS support Phase III advancement Median overall survival (mOS) of 13.4 months in r/r HR-MDS patients (n=32) treated with bexmarilimab + azacitidine; mOS of 9.3 months in TP53 mutated patients (n=13) ORR of 85% and cCR of 50% in patients with frontline MDS (n=20) Deep bone marrow responses demonstrated at all dose levels in...
Read moreReputed to be a leading research and development (R&D) hub for medical sciences, Hong Kong hosts the world's largest and most significant gathering of stem cell research and regenerative medicine, the International Society of Stem Cell Research (ISSCR) 2025 Annual Meeting. The event is brought to Hong Kong for the first time, thanks to the joint effort of three local universities - The University of Hong Kong, The Chinese University of Hong Kong...
Read more
Aspira Women's Health Inc., ("Aspira") (OTCQB:AWHL), an AI enhanced bio-analytics based women's health company focused on delivering leading noninvasive gynecologic disease diagnostic and disease management tools, announces an update from the Advanced Research Projects Agency for Health's ( ARPA-H ) Sprint for Women's Health program initiative to address critical unmet needs in women's health. Aspira was originally awarded a $10 Million award...
Read more
Vitro Biopharma Inc. today announced that its AlloRx stem cell therapy was prominently featured in a New York Times article discussing the future of experimental therapies in the United States. The article, published June 5, 2025, examines Health Secretary Robert F. Kennedy Jr.'s recent policy statements on expanding patient access to regenerative medicine and explores the evolving regulatory landscape for treatments like stem cell therapies....
Read more
Moolec Science SA (NASDAQ:MLEC) "The Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, today announced that it regained compliance with Listing Rule 5550(a)(2) (the "Bid Price Rule"), as required by the Nasdaq Hearings Panel's ("Panel") decision dated April 3, 2025. On May 14, 2025, the Company effected a 1-for-10 reverse stock split, and the common shares have since...
Read more
